Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release

Am J Physiol. 1993 Aug;265(2 Pt 1):C337-42. doi: 10.1152/ajpcell.1993.265.2.C337.

Abstract

An antiarrhythmic agent, disopyramide, was found to enhance the insulin secretory capacity of Wistar rat pancreatic islets with a half-maximal concentration of 23.3 microM. Employing a patch-clamp technique, disopyramide was found to inhibit ATP-sensitive K+ (KATP) channel activity in rat pancreatic beta-cells in primary culture without altering the unitary conductance. Half-maximal inhibition was achieved by the addition of 3.6 microM disopyramide to the intracellular bathing solution in the inside-out mode, 11.0 microM to the extracellular bathing solution in the outside-out mode, and 87.4 microM in the cell-attached mode. The binding of [3H]glibenclamide to pancreatic islets was inhibited by unlabeled glibenclamide but not by unlabeled disopyramide. Based on these observations, it is concluded that disopyramide blocks pancreatic KATP channels via binding to a site(s) distinct from the sulfonylurea receptor. This effect may be causatively involved in disopyramide-induced hypoglycemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / pharmacology*
  • Animals
  • Disopyramide / pharmacology*
  • Dose-Response Relationship, Drug
  • Electrophysiology / methods
  • Glyburide / metabolism
  • Glyburide / pharmacology
  • In Vitro Techniques
  • Insulin / metabolism*
  • Islets of Langerhans / metabolism*
  • Male
  • Osmolar Concentration
  • Potassium Channels / drug effects*
  • Potassium Channels / metabolism*
  • Rats
  • Rats, Wistar

Substances

  • Insulin
  • Potassium Channels
  • Adenosine Triphosphate
  • Disopyramide
  • Glyburide